
View: India has negotiated well with Trumpian policy, but it may have to take a stand soon
But, now, we may be headed for more interesting times as India takes over the rotating presidency of BRICS. Trump's already announced in January that any effort by the grouping towards de-dollarisation could result in 100% tariffs. This month, he said that alleged 'anti-American policies' by BRICS could attract an additional 10% tariff.
As on other issues, GoI has no intention of challenging the US either on de-dollarisation or any anti-American move, and the PM has said so repeatedly. But holding BRICS presidency, India might find itself as collateral casualty. As it is, individually three principal BRICS countries - Russia, China, South Africa - are the target of Trump's ire. India has, along with other countries, so far escaped 'Liberation Day' reciprocal tariffs. But it ran square into Trump in the wake of Operation Sindoor. Countering the Indian narrative, Trump has insistently claimed he worked out the ceasefire and is ready to mediate on the Kashmir issue. The only weapon New Delhi has had is to politely ignore the issue, even as Pakistan has rubbed it in by supporting Trump's candidature for the Nobel Peace Prize.It's not just luck but a lot of hard work that has kept India on the right side of Trump. Recall that in the run-up to Trump's inaugural, S Jaishankar was in Washington for nearly a week at the end of December last year, working the US Congress, MAGA-leaning officials and prospective cabinet officials. He was aided by foreign secretary Vikram Misri and Indian ambassador V M Kwatra.The agenda was to connect early with the incoming administration and see if the president could be persuaded to come to India for the Quad Summit to be hosted by India later this year. There was some talk about a potential Modi invite for the inaugural. But, in the end, it was Jaishankar who bagged a privileged front-row seat on January 20. Subsequently, there was an effort to get a Modi visit to Washington in February. But that, too, did not pan out.As soon as it became clear that Trump was winning the elections, trade officials in India began to prepare for the incoming administration. Bilateral trade between India and the US exceeded $118 bn in 2023-24, where India enjoyed a $32 bn trade surplus.Plans were shaped to offer tax cuts on farm products and key imports, high-end medical devices, motorcycles, as well as enhance the purchase of LNG and defence equipment. Indian officials pitched the idea that the country could replace China as an alternative manufacturing base. New Delhi saw a niche for India as a supplier of low-end products as part of the supply chain of the 'Make in America' programme.In January, India also aligned itself with another element of the Trump programme. It agreed to take back 18,000 India nationals who were set to be deported by the US. New Delhi made it clear that it would cooperate in any action against illegal migrants.But, soon, it became clear that the Trump regime was not differentiating between friends and enemies. 'Liberation day' reciprocal tariffs hit India at 26%. The regime soon walked back on them on account of the market crash and said they would be paused for 90 days as of April 9 at 10%, which has been now extended till August 1.Now, the tariff clock is ticking, as the US and India race to complete their trade deal. Wild cards are scattered all around. There is the issue of 50% tariffs on copper, and a threatened 200% on pharma products that could be devastating for India.Separately - and since this is germane to India's hopes - the US seems to have arrived at a framework agreement with China. Details are scarce, but China seems to have made it easier for the US to acquire Chinese rare earths and rare minerals magnets - though average US tariffs remain at 51.1% and China's at 32.6%.The Brazil BRICS summit was, despite all the hoopla and tough language on trade, a bit of a letdown. Two of its leading lights - R and C - Vladimir Putin and Xi Jinping, stayed away. As it is, expansion of the bloc to include Egypt, Ethiopia, Iran, the UAE and Indonesia has diluted even the limited coherence it had.Last week at the summit, Modi declared that 'under India's BRICS presidency, we will work to define BRICS in a new form'. In his characteristic 'acronymous' style, he said BRICS would stand for 'Building Resiliency and Innovation for Cooperation and Sustainability', an agenda that would give priority to 'global south' issues, rather than challenging the developed world on issues relating to trade and global governance, let alone currency.Clearly, India has no intention of straying into the crosshairs of Trump's sights. But the problem is that US policies - whether on trade, stability of the dollar or Pakistan - could leave it with no options but to react and face the Trump bullets head-on. (Disclaimer: The opinions expressed in this column are that of the writer. The facts and opinions expressed here do not reflect the views of www.economictimes.com.) Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. Markets need to see more than profits from Oyo
As GenAI puts traditional BPO on life support, survival demands a makeover
Is gold always the best bet? Think again
Why this one from 'Dirty Dozen', now in Vedanta fold, is again in a mess
Can Indian IT protect its high valuation as AI takes centre stage?
F&O Radar| Deploy Bull Call Spread in Nifty for gains from volatility amid uptrend
Aggressive? Yes, but better for investors with a risk appetite: 6 small private bank stocks with upside potential up to 36% in 1 year
In mid-caps, 'just hold' often creates wealth: 10 mid-cap stocks from different sectors with upside potential up to 44%
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Indian Express
37 minutes ago
- Indian Express
India begins crucial week-long trade negotiations with US
Days after US President Donald Trump announced fresh reciprocal tariff rates of up to 50 per cent for scores of countries, including the European Union, Canada, Brazil and ASEAN among others, Indian negotiators have begun a fresh round of talks in Washington to clinch a deal before August 1. 'India's aim is to sign a bilateral trade deal by the end of the year. The week-long negotiations have begun and the interim trade deal will depend on the willingness of both sides. If substantial agreement is reached, an interim agreement can be reached,' a senior government official said on Monday. Another official, seeking anonymity, said that India is in an advantageous position compared to other countries, particularly its Asian peers, and that the likelihood of India reaching a trade deal with the US is high. The ongoing round of negotiation comes less than 10 days after Indian officials, led by Special Secretary Rajesh Agarwal, returned from Washington on July 4. The Indian Express had reported that agriculture has been a major sticking point in the negotiations, particularly because India has adopted an unwavering stance on this sector. The US maintains that the August 1 cut-off date is not a new deadline but an outer limit for countries to 'speed things up', and that this strategy has helped bring trading partners such as the European Union on board. US Treasury Secretary Scott Bessent, when asked in a TV interview if there was a playbook for the US tariffs actions, said: 'The playbook is to apply maximum pressure. You know, we saw that the EU was very slow in coming to the table. Three weeks ago, on a Friday morning, President Trump threatened 50 per cent tariffs. And within a few hours, five of the European national leaders had called him. Ursula von der Leyen, the head of the EU, was on the phone and the EU is making very good progress. They were off to a slow start.' The threat from the Trump administration is that if the August 1 deadline is not adhered to, those countries go back to the April 2 tariff levels. Most of them are minor trading partners of the US and are likely outside America's 18 important trading relationships that account for 95 per cent of the country's trade deficit. Ravi Dutta Mishra is a Principal Correspondent with The Indian Express, covering policy issues related to trade, commerce, and banking. He has over five years of experience and has previously worked with Mint, CNBC-TV18, and other news outlets. ... Read More

Mint
44 minutes ago
- Mint
Sun Pharma launches alopecia drug Leqselvi in US after settling patent dispute
Sun Pharma on Monday announced it has settled a patent row with American biopharma company Incyte Corporation over its hair-loss drug, paving the way for its launch in the US. The Mumbai-based drugmaker, embroiled in the lawsuit since last year, launched the specialty drug in the world's largest pharmaceutical market on Monday. Leqselvi (oral deuruxolitinib) is indicated for treatment of adults with severe alopecia areata. Under the terms of settlement and licensing agreement, the two companies will seek a dismissal of the pending litigation in the United States District Court for the District of New Jersey, the company said in a release. Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation. Incyte has also granted a limited, non-exclusive licence to Sun to US patents no. 9,662,335 and other related patents. This licence covers oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications including alopecia areata, the company said. In return, Sun will pay Incyte an upfront amount, as well as ongoing royalty payments until expiry of the patents. The company did not reveal other specific terms of the settlement. In April 2025, Sun Pharma received a favourable ruling from the US Court of Appeals for the Federal Circuit, which vacated a preliminary injunction on Leqselvi's launch, lifting restrictions on the launch. Sun received approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator's approval, Incyte Corporation filed a patent infringement lawsuit against Sun Pharma, alleging that Leqselvi infringed upon its existing patents, delaying the launch. In November 2024, the US District Court of New Jersey granted a preliminary injunction, halting Leqselvi's launch in the US until the lawsuit was resolved. Sun Pharma on Monday announced the launch of Leqselvi in the US, in a separate release. The drug will be available for prescription in 8mg tablets in the country. 'As a company committed to launching new therapeutic options which address the unmet needs of patients, adding LEQSELVI to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community," said Richard Ascroft, CEO, Sun Pharma North America, in the release. Leqselvi demonstrated rapid results in clinical trials with one third of patients regaining almost all of their hair by week 24. Some patients (3%) achieved 80% or more scalp coverage as fast as 8 weeks. Leqselvi is expected to be a $200 million opportunity for Sun Pharma in 3-4 years after launch, according to brokerage Elara Capital. Sun Pharma's shares ended 0.58% higher at ₹ 1,681.70 apiece on NSE on Monday.
&w=3840&q=100)

Business Standard
an hour ago
- Business Standard
The margin trap: Why innovation matters more than short-term profits
India needs to get on the innovation cycle - and everyone has a part to play. The government must provide basic funding and strengthen linkages between industry and academia Akash Prakash Listen to This Article One of the clear takeaways when speaking with senior people working with Apple is their disappointment at the lack of willingness among India Inc to step up and make the investments needed to bring the Apple ecosystem into India. While China is putting up obstacles, the profit focus of Indian entrepreneurs is also a stumbling block. Whether it is putting up the component supply chain or making large capital investments for display units, there is a lack of interest on the part of large Indian groups to commit capital. They cite the low margins on offer and the intense scrutiny